|
|
Article: Canadian Companies Inflazyme, GlycoDesign Plan C$12.8M Merger.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
The tough global biotechnology times are forcing a lot of companies to do a lot of things - reduce staff, refocus research, scramble for money and even file for Chapter 11 protection. They also are opening avenues for industry consolidation, an example being the planned C$12.8 million merger between Inflazyme Pharmaceuticals Ltd. and GlycoDesign Inc.
The definitive agreement has Inflazyme, of Vancouver, British Columbia, issuing 22 million shares to acquire the outstanding stock of Toronto-based GlycoDesign. Based on the 10-day average closing price of C58 cents for Inflazyme shares on the Toronto Stock Exchange leading up to ...
Related newspaper, magazine, and journal articles:
|
|
Article: STOCK GAINS 57 PERCENT ON NEWS INFLAZYME, HOECHST IN $91M ...
BIOWORLD Today;
February 10, 1999 ;
700+ words
... ... and respiratory disease. Inflazyme get rights to oral and ... strong science skills," Inflazyme president and CEO Ian McBeath told BioWorld Today. "The deal involves milestones ... of this partnership." Inflazyme's stock (VSE:IZP ...
|
|